Latest Ore Pharmaceuticals (ORXE) Headlines
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Ore Holdings Approves Debt-for-Equity Exchange
Business Wire - Tue Nov 12, 4:40PM CST
Ore Holdings, Inc. (OTC: ORXE.PK) today announced that its board of directors, following an evaluation of strategic alternatives, has approved an agreement under which the company will issue newly created convertible preferred shares to Steel Partners, Ltd., in exchange for the cancellation of a 12% secured promissory note, pursuant to an exchange proposal made by privately-held Steel Partners, Ltd.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Functional Dyspepsia
M2 - Mon Sep 02, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbqxmb/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. Functional (Non Ulcer) Dyspepsia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Functional (Non Ulcer) Dyspepsia. - A review of the Functional (Non Ulcer) Dyspepsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Functional (Non Ulcer) Dyspepsia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Eisai Co., Ltd. - Zeria Pharmaceutical Co Ltd - Ore Pharmaceuticals Inc - AGI Therapeutics plc - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/lb...tional_non About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Gastric Ulcers - Pipeline Review, H1 2013
M2 - Thu Jul 18, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t63njg/gastric_ulcers) has announced the addition of the "Gastric Ulcers - Pipeline Review, H1 2013" report to their offering. 'Gastric Ulcers - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Ulcers. Scope - A snapshot of the global therapeutic scenario for Gastric Ulcers. - A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Gastric Ulcers Therapeutics Development - Takeda Pharmaceutical Company Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ore Pharmaceuticals Inc - Sihuan Pharmaceutical Holdings Group Ltd. - HeliCure AB Drug Profiles - vonoprazan - DWJ-206 - Helicobacter Pylori Vaccine - ebselen - PMKS-005 - Acid Pump Antagonists - Anaprazole For more information visit http://www.researchandmarkets.com/research/t6...ric_ulcers
Ulcers - Pipeline Review, H1 2013
M2 - Fri Jul 12, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fgbql/ulcers_pipeline) has announced the addition of the "Ulcers - Pipeline Review, H1 2013" report to their offering. The research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Scope - A snapshot of the global therapeutic scenario for Ulcers. - A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-spec
Ore Pharmaceuticals Inc - Product Pipeline Review - 2012
M2 - Mon Feb 18, 4:08AM CST
Summary
Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Ore Holdings Approves Debt-for-Equity Exchange
Business Wire - Tue Nov 12, 4:40PM CST
Ore Holdings, Inc. (OTC: ORXE.PK) today announced that its board of directors, following an evaluation of strategic alternatives, has approved an agreement under which the company will issue newly created convertible preferred shares to Steel Partners, Ltd., in exchange for the cancellation of a 12% secured promissory note, pursuant to an exchange proposal made by privately-held Steel Partners, Ltd.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Functional Dyspepsia
M2 - Mon Sep 02, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbqxmb/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. Functional (Non Ulcer) Dyspepsia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Functional (Non Ulcer) Dyspepsia. - A review of the Functional (Non Ulcer) Dyspepsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Functional (Non Ulcer) Dyspepsia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Eisai Co., Ltd. - Zeria Pharmaceutical Co Ltd - Ore Pharmaceuticals Inc - AGI Therapeutics plc - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/lb...tional_non About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Gastric Ulcers - Pipeline Review, H1 2013
M2 - Thu Jul 18, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t63njg/gastric_ulcers) has announced the addition of the "Gastric Ulcers - Pipeline Review, H1 2013" report to their offering. 'Gastric Ulcers - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Ulcers. Scope - A snapshot of the global therapeutic scenario for Gastric Ulcers. - A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Gastric Ulcers Therapeutics Development - Takeda Pharmaceutical Company Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ore Pharmaceuticals Inc - Sihuan Pharmaceutical Holdings Group Ltd. - HeliCure AB Drug Profiles - vonoprazan - DWJ-206 - Helicobacter Pylori Vaccine - ebselen - PMKS-005 - Acid Pump Antagonists - Anaprazole For more information visit http://www.researchandmarkets.com/research/t6...ric_ulcers
Ulcers - Pipeline Review, H1 2013
M2 - Fri Jul 12, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fgbql/ulcers_pipeline) has announced the addition of the "Ulcers - Pipeline Review, H1 2013" report to their offering. The research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Scope - A snapshot of the global therapeutic scenario for Ulcers. - A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-spec
Ore Pharmaceuticals Inc - Product Pipeline Review - 2012
M2 - Mon Feb 18, 4:08AM CST
Summary
Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team
